Table 1. Patient characteristics.
| Variables | Spontaneous clearance (n = 1255) | Response to treatment (n = 362) |
||||
|---|---|---|---|---|---|---|
| Chronic (n = 795) N(%) | Resolver (n = 460) N(%) | P value | N-SVR (n = 125) N(%) | SVR (n = 237) N(%) | P value | |
| Age, yeara | 52.44 ± 12.30 | 47.05 ± 14.04 | <0.001 | 53.91 ± 8.06 | 53.20 ± 8.81 | 0.456 |
| Gender | 0.017 | 0.883 | ||||
| Male | 301 (37.9) | 206 (44.8) | 30 (24.0) | 59 (24.9) | ||
| Female | 494 (62.1) | 254 (55.2) | 95 (76.0) | 178 (75.1) | ||
| Viral genotype | 0.002 | |||||
| 1 | 635 (81.9) | 300 (74.1) | 124 (100) | 237 (100) | ||
| 2 or 3 | 140 (18.1) | 105 (25.9) | 0 | 0 | ||
| AST (IU/L) | <0.001 | 0.038 | ||||
| <40 | 468 (58.9) | 340 (73.9) | 47 (37.6) | 117 (49.4) | ||
| ≥40 | 327 (41.1) | 120 (26.1) | 78 (62.4) | 120 (50.6) | ||
| ALT (IU/L) | 0.015 | 0.055 | ||||
| <40 | 509 (64.0) | 338 (73.5) | 39 (31.2) | 99 (41.8) | ||
| ≥40 | 286 (36.0) | 122 (26.5) | 86 (68.8) | 138 (58.2) | ||
| HCV RNA (IU/L) | <0.001 | |||||
| <106 | 33 (26.4) | 113 (47.7) | ||||
| ≥106 | 92 (73.6) | 124 (52.3) | ||||
| Platelets (109/L) | 0.039 | |||||
| <140 | 81 (64.8) | 126 (53.2) | ||||
| ≥140 | 44 (35.2) | 111 (46.8) | ||||
| ALB (g/L)b | 43.6 (40.8–46.2) | 43.6 (40.9–46.2) | 0.607 | |||
| TP (g/L)b | 78 (73.8–82.5) | 78.1 (74.3–81.5) | 0.920 | |||
| WBC (109/L)b | 4.9 (3.9–6.1) | 4.6 (3.7–5.5) | 0.065 | |||
| AFP (ng/mL) b | 3.8 (2.4–7.4) | 3.3 (2.0–6.8) | 0.160 | |||
| HGB (g/L)b | 139 (125–146) | 133.5 (121–145) | 0.056 | |||
| GLU (mmol/L)b | 5.5 (5.1–6.4) | 5.6 (4.9–6.2) | 0.531 | |||
Abbreviation: N-SVR, non sustained virological response; SVR, sustained virological response; Non-1b, genotype 2, 3; AST, aspartate transaminase; ALT, alanine aminotransferase; ALB, albumin; TP, total protein; WBC, white blood cell; AFP, alpha fetal protein; HGB, hemoglobin; GLU, glucose.
aMean ± standard deviation.
bMedian and interquartile range.